CDKN2A and tonsil neoplasm: A total of 29.25% of the tonsillar tumors (TT) were diagnosed in Stage III (TT-III), of which 2.20% showed a negative reaction for both the anti-p16 antibody and the anti-HPV antibody (TT-III-NN), 1.89% presented a negative reaction for the anti-p16 antibody and a positive reaction for the anti-HPV antibody (TT-III-NP), 0.94% presented a positive reaction for the anti-p16 antibody and a negative reaction for the anti-HPV antibody (TT-III-PN) and 24.21% showed a positive reaction for both the anti-p16 antibody and the anti-HPV antibody (TT-III-PP).